AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

This study has been terminated.
(Administratively complete.)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: January 25, 2007
Last updated: March 13, 2013
Last verified: March 2013
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Condition Intervention Phase
Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Drug: cediranib maleate
Other: laboratory biomarker analysis
Procedure: computed tomography
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Other: pharmacological study
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of AZD2171 in Hepatocellular Carcinoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    This design yields at least 90% power to detect a true 3-month PFS rate of at least 69%.

Secondary Outcome Measures:
  • Response rate [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: The time from study entry until death from any cause, assessed up to 1 year ] [ Designated as safety issue: No ]
    Overall survival will be calculated using the Kaplan-Meier method, and confidence limits for survival estimates will be calculated using the Greenwood formula.

Enrollment: 34
Study Start Date: May 2009
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients will receive AZD2171 by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies.
Drug: cediranib maleate
Given orally
Other Names:
  • AZD2171
  • Recentin
Other: laboratory biomarker analysis Procedure: computed tomography
Other Name: tomography, computed
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Other Name: DCE-MRI
Other: pharmacological study
Other Name: pharmacological studies

Detailed Description:


I. Assess the progression free survival of patients with locally advanced unresectable or metastatic hepatocellular carcinoma treated with AZD2171.


I. Determine the toxicity of this drug in these patients. II. Determine, preliminarily, the efficacy of this drug, in terms of response rate, duration of response, and overall survival, in these patients.

III. Determine the blood flow changes and vascular permeability of the tumor in patients treated with this drug.

IV. Determine the pharmacokinetic profile of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Dynamic contrast-enhanced (DCE) MRI and CT perfusion scan of the liver are performed at baseline, 72 hours after the initial dose of AZD2171, and at the end of course 1. Blood samples for pharmacokinetic studies are collected periodically during study.

After the completion of study treatment, patients are followed every 3 months for 1 year.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed hepatocellular carcinoma
  • Locally advanced unresectable OR metastatic disease
  • Cancer of the Liver Italian Program (CLIP) score =< 3
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Measurable disease, defined as >= 1 unidimensionally measurable lesion>= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan
  • Cardiac arrhythmia
  • Measurable lesion must be outside field of prior chemoembolization
  • No known brain metastases
  • ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
  • Life expectancy > 12 weeks
  • Absolute neutrophil count >= 1,000/mm^3
  • Platelet count >= 75,000/mm^3
  • Hemoglobin >= 8 g/dL
  • Bilirubin =< 3.0 mg/dL
  • AST and ALT =< 7 times upper limit of normal
  • Creatinine =< 2.0 mg/dL
  • Fertile patients must use effective contraception
  • CLIP score =< 3
  • Not pregnant or nursing
  • Negative pregnancy test
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD2171
  • No chronic diarrhea or any disorder that would limit adequate absorption of AZD2171
  • No familial history of long QT syndrome
  • Proteinuria =< +1 on two consecutive dipsticks taken no less than 1 week apart
  • No other uncontrolled illness including, but not limited to, any of the following:
  • Hypertension
  • Ongoing or active infection
  • No psychiatric illness or social situation that would limit study compliance
  • Recovered from prior therapy
  • Prior systemic chemotherapy regimens for hepatocellular carcinoma allowed
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
  • More than 4 weeks since prior radiotherapy, major surgery, or chemoembolization
  • At least 30 days since prior participation in an investigational trial
  • No other concurrent investigational agents
  • No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, or pentamidine)
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No other concurrent anticancer agents or therapies
  • No mean QTc > 470 msec (with Bazett's correction) on screening EKG (490 msec for women)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00427973

United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Andrew Zhu Massachusetts General Hospital
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00427973     History of Changes
Other Study ID Numbers: NCI-2009-00130  DFCI IRB 05-311  N02CO12400  CDR0000526405 
Study First Received: January 25, 2007
Last Updated: March 13, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Liver Neoplasms
Carcinoma, Hepatocellular
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors processed this record on May 26, 2016